A small but growing set of clinical trials suggests that GLP-1 medications may improve several core features of PMOS, the hormonal condition formerly called polycystic ovary syndrome, including irregular periods, elevated testosterone, and insulin resistance. The findings were detailed in Associated Press reporting published this weekend.
The evidence is early. The trials involve small numbers of participants, no GLP-1 drug is approved to treat the condition, and independent reviewers describe the certainty of the data as low. What is not in dispute is that prescribing is already happening off-label, and that insurance denials are now a practical barrier standing between many patients and a medication their doctor has recommended.
That gap is the immediate household issue. PMOS affects roughly one in eight women worldwide, more than 170 million people, and for many families, the question is no longer whether the drug might help but whether they can afford to find out.
Three Trials, Consistent Direction, Small Numbers
Dr. Melanie Cree, a professor at the University of Colorado Anschutz Medical Campus, has led three studies testing GLP-1 drugs for the condition. Early data from one of them, published in June in the journal Fertility and Sterility, reported that eight of eleven participants who completed the trial lost at least 10 percent of their body weight. Among those participants, the median weight loss was about 42 pounds, and the median drop in testosterone was 52 percent. Six women had more frequent periods, and four returned to monthly cycles.
Across all three of Cree's studies, women taking GLP-1 drugs lost more weight than control groups, and levels of testosterone, blood sugar, and insulin fell. One study examined weekly semaglutide injections, another an oral semaglutide tablet, and a third exenatide injections.
Cree has described the underlying rationale in early semaglutide findings from her research group: women with PMOS frequently face a choice between treatments aimed at reproductive symptoms and treatments aimed at metabolic health, and rigorous data on how these drugs affect fertility and reproductive function in this population is still scarce. Many women with PMOS have insulin resistance regardless of body size, and high insulin can drive the ovaries to produce more testosterone, which in turn contributes to skipped periods, severe acne, and unwanted hair growth.
Independent Reviews Land More Cautiously
A systematic review in the European Journal of Endocrinology reached a more restrained conclusion. Pooling 11 randomized controlled trials, the authors found that GLP-1 receptor agonists used as an add-on therapy reduced body mass index by an average of 1.38 units compared with control groups, a finding they rated low certainty.
The review found no difference between groups for LDL cholesterol or triglycerides, and concluded that the available evidence was insufficient to draw conclusions about glucose, insulin, hirsutism, or menstrual regularity. It identified no studies at all assessing quality of life, mental health, or cost effectiveness, and called for well designed longer term randomized trials.
That last point matters for reading the trial results above. The outcomes Cree's studies report most encouragingly, testosterone and cycle frequency, are precisely the outcomes the pooled review found too thin to judge. The honest summary is that the direction of findings is consistent, while the strength of evidence is not yet sufficient to change treatment guidelines. These are small trials measuring intermediate markers, not large trials measuring long-term fertility, cardiovascular, or pregnancy outcomes. Weight regain after stopping is documented, and the drugs do not work for everyone.
Coverage Denials Are Doing the Rationing
Because no GLP-1 drug carries an approved indication for PMOS, prescriptions written for it are off-label, and insurers frequently decline to pay. Some plans also exclude the same drugs for weight management, which removes the alternative pathway.
Dr. Rana Malek, an endocrinologist with the University of Maryland Medical System, told the Associated Press that "I use these medicines a great deal," typically to support weight loss in patients with insulin resistance, and said insurance problems keep many patients from obtaining them.
The AP account illustrates how that plays out. One trial participant in Colorado saw her abnormal hair growth slow and her periods normalize during ten months of weekly semaglutide injections. When her study participation ended, the free medication ended with it, and her family turned to appeals and manufacturer assistance programs.
Patients facing a denial can ask their prescriber about prior authorization, a formal appeal, documentation of insulin resistance or a diabetes diagnosis where applicable, and manufacturer patient assistance programs. Medicare's prescription drug coverage rules and state Medicaid formularies differ, so the answer depends heavily on the plan.
The Name Changed This Year, and That Matters for Search
Readers may encounter this condition under two names. A global consensus process published in The Lancet renamed it in May, shifting emphasis away from ovaries and cysts toward the endocrine and metabolic features that drive it. The process drew on surveys of thousands of patients and clinicians and involved more than 50 patient and professional organizations, with a three-year transition period now underway. MedicalDaily previously covered the reasoning behind the renaming.
Diagnosis often takes years because symptoms overlap with other conditions and vary widely between patients. Standard management remains symptom-directed, commonly involving hormonal contraceptives to regulate cycles, metformin for insulin resistance, and attention to diet and activity.
Nothing in the new research changes current medical recommendations. No professional society has issued guidance endorsing GLP-1 drugs as a PMOS treatment, and larger trials are underway, including one evaluating whether weight loss and metabolic improvement can restore ovulation. Anyone considering these medications should discuss them with a clinician who can review their full metabolic picture, and should not obtain them from unverified online sellers.
For patients whose symptoms have been dismissed for years, the more immediately useful step may be simpler than a prescription. Asking a clinician to test fasting insulin, glucose, and testosterone establishes whether insulin resistance is present, which is the finding that shapes every subsequent treatment conversation.
Key Questions Answered
What did the new trial data show? In one trial published in Fertility and Sterility, eight of eleven completers lost at least 10 percent of body weight, with a median testosterone drop of 52 percent and improved menstrual regularity in six participants.
Are GLP-1 drugs approved to treat PMOS? No. Prescribing them for PMOS is off-label. They are approved for type 2 diabetes and, in some formulations, chronic weight management.
How strong is the evidence? Limited. A systematic review of 11 randomized trials found a modest reduction in body mass index rated low certainty, and insufficient evidence on menstrual regularity, insulin, and hirsutism.
Why is insurance a problem? Because there is no approved indication for PMOS, insurers often deny coverage, and some plans separately exclude these drugs for weight management.
What can patients do about a denial? Ask the prescriber about prior authorization, a formal appeal, supporting documentation of insulin resistance, and manufacturer patient assistance programs.
What are the common side effects? Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are the most frequently reported. Weight can return after stopping the medication.
Has treatment guidance changed? No. Current medical recommendations for PMOS have not changed; no professional society endorses these drugs for the condition, and larger trials are still in progress.
